Oroxylin A: A promising flavonoid for prevention and treatment of chronic diseases

A Sajeev, M Hegde, S Girisa, TN Devanarayanan… - Biomolecules, 2022 - mdpi.com
There have been magnificent advancements in the understanding of molecular mechanisms
of chronic diseases over the past several years, but these diseases continue to be a …

Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015–2018)

X He, X Chen, H Zhang, T Xie, XY Ye - Expert Opinion on …, 2019 - Taylor & Francis
ABSTRACT Introduction: Tyrosine kinase 2 (Tyk2) is a non-receptor tyrosine-protein kinase,
an enzyme that in humans is encoded by the TYK2 gene. Tyk2, together with three other …

[PDF][PDF] The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib

EHS Choy, C Miceli-Richard… - Clinical and …, 2019 - orca.cardiff.ac.uk
Numerous cytokines have been implicated in the pathogenesis of inflammatory diseases,
and their dysregulation is a main feature of rheumatoid arthritis (RA). Cytokines stimulate …

One year in review 2019: novelties in the treatment of rheumatoid arthritis

E Silvagni, M Di Battista, A Bonifacio… - Clinical and …, 2019 - boa.unimib.it
The current treatment approach in rheumatoid arthritis (RA) follows a stepwise management,
starting from early introduction of conventional synthetic (cs) disease-modifying anti …

Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the RECord linkage On Rheumatic …

G Carrara, A Bortoluzzi, G Sakellariou… - Clinical and …, 2019 - boa.unimib.it
Objective The aims of this study were to define the risk of serious bacterial infections in
patients receiving specific biological disease-modifying anti-rheumatic drugs (bDMARDs) …

Theaflavin-3, 3′-digallate attenuates rheumatoid inflammation in mice through the nuclear factor-κB and MAPK pathways

W Liu, J Li - Archivum immunologiae et therapiae experimentalis, 2019 - Springer
Rheumatoid arthritis (RA) is a common autoimmune disease which impacts a large number
of patients worldwide, and new drugs are required for lower the disease burden. Theaflavin …

[PDF][PDF] One year in review 2018: axial spondyloarthritis

L Carli, E Calabresi, G Governato, J Braun - Clin Exp Rheumatol, 2019 - i.clinref.com
Spondyloarthritis (SpA) is the umbrella term for a broad spectrum of inflammatory rheumatic
diseases with typical but also rather different clinical manifestations, limited laboratory …

[PDF][PDF] One year in review 2018: gout

L Punzi, A Scanu, P Spinella, P Galozzi… - Clin Exp …, 2019 - clinexprheumatol.org
Gout is the most common form of inflammatory arthropathy, and is associated with
excruciating pain, major impairment of quality of life, and increased risk of comorbidities and …

[PDF][PDF] One year in review 2018: psoriatic arthritis

E Calabresi, S Monti, G Governato… - Clin Exp Rheumatol, 2019 - clinexprheumatol.org
Spondyloarthritis (SpA) is an inflammatory condition characterised by a broad spectrum of
clinical manifestations, laboratory abnormalities and imaging features that genetically tend …

Body mass index and persistence of conventional DMARDs and TNF inhibitors in rheumatoid arthritis

CB McCulley, JL Barton, GW Cannon… - Clinical and …, 2018 - pmc.ncbi.nlm.nih.gov
Objective Obese patients with rheumatoid arthritis (RA) may be more likely to discontinue
therapy than non-obese patients, possibly signifying a more refractory phenotype. The …